Stocktoria

Getinge AB (publ) GETI-B.ST

SE · Nasdaq Stockholm · XSTO · stock · Healthcare · website

Getinge AB (publ) (GETI-B.ST) earns a Piotroski F-score of 8/9 (strong financial health), with an Altman Z″ in the safe zone. It pays a dividend yielding 2.27% (safety: moderate). FY2025 revenue was kr 35.0B at a 6.5% net margin.

Chart by TradingView
8/9
Piotroski F — financial health
3.4
Altman Z″ — distress risk · safe
2.2%
Dividend yield 5y avg · moderate · Dividend payout 56.1%

Quality score trend · recomputed for each fiscal year

Piotroski F /9
6 5 8 202320242025
Altman Z″
3.46 2.87 3.40 202320242025

Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.

kr 204.80 as of 2026-07-01 · +6.1% 1y
kr 183.55kr 223.3052-wk
Market cap USD$5.4B
P / E24.7×
Dividend yield 5y avg2.2%
Net margin 5y avg6.9%
Return on equity 5y avg7.2%
Beta0.79
Employees11,754

Analyst price target

kr 227.20 +10.9% vs last
consensus: buy · 10 analysts
target range kr 165.00 – kr 270.00

Wall Street analyst consensus — a sentiment gauge, not our scoring.

Revenue trend · last 4y · up

How it ranks in Healthcare · percentile among 79 companies

Piotroski Fstronger than 78%
Net marginstronger than 26%
Return on equitystronger than 29%
Revenue growthstronger than 19%

Percentile vs other Healthcare companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.

Piotroski F breakdown · 8/9 tests passed

Altman Z″ components · safe zone

ComponentValue
Working capital / assets0.074
Retained earnings / assets0.381
EBIT / assets0.079
Equity / liabilities1.089

About Getinge AB (publ)

Getinge AB (publ) provides products and solutions for operating rooms, intensive-care units, and sterilization departments in Sweden and internationally. The company operates through Acute Care Therapies, Life Science, and Surgical Workflows segments. It offers extracorporeal membrane oxygenation, mechanical ventilation, advanced patient monitoring, ICU infrastructure equipment, and drainage solutions. In addition, the company provides surgical perfusion, endoscopic vessel harvesting, intra-aortic balloon counterpulsation, vascular and cardiothoracic surgery equipment, peripheral stenting, OEM solutions, and beating heart surgery equipment; and operating room equipment, anesthesia, advanced patient monitoring, and operating room integration solutions. Further, it offers pre-cleaning, cleaning and disinfection, sterilization, consumables, endoscope reprocessing, and sterile supply management solutions; connected medical devices, and patient flow management; and low temperature sterilization, biocontainment in vaccine production, terminal sterilization, sterile isolation technology, cleaning and sterilization, aseptic transfer, and large-scale cultivation. Additionally, the company provides bioreactor preparation solution, bioprocess development and optimization, labware cleaning and sterilization, biocontainment, and vivarium. It offers its products through a network of sales companies, as well as through agents and distributors in the Americas, Europe, the Middle East, Africa, and the Asia and Pacific. Getinge AB (publ) was founded in 1904 and is headquartered in Gothenburg, Sweden.

FAQ

Is GETI-B.ST financially healthy?

Getinge AB (publ)'s Piotroski F-score is 8/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.

Does GETI-B.ST pay a dividend, and is it safe?

Yes. Getinge AB (publ) pays a dividend yielding about 2.27% with a 56.1% payout ratio, rated “moderate” for safety.

How profitable is GETI-B.ST?

In FY2025, Getinge AB (publ) had a net margin of 6.5% and a return on equity of 7.7%.

Is GETI-B.ST overvalued or undervalued?

Getinge AB (publ) trades at about 24.7× trailing earnings — near its 10-year norm (10-year range 23.6×–36.3×, median 25.6×). Stocktoria reports the data, not buy/sell advice.

What is the analyst price target for GETI-B.ST?

The average Wall-Street price target for Getinge AB (publ) is kr 227.20, about 10.9% above the recent price, from 10 analysts (consensus: buy).

Is GETI-B.ST a good stock to buy?

Stocktoria doesn't give buy or sell advice, but here is the data on Getinge AB (publ): a Piotroski F-score of 8/9, an Altman Z″ in the safe zone, a P/E of about 24.7×, a dividend yield of 2.27%. Weigh these quality and valuation signals against your own goals.

Computed from company filings · SE · as of 2025-12-31. Figures in SEK. Facts plus Stocktoria's own computed scores — not investment advice.